This study demonstrates that IGF2-AS is selectively upregulated in tamoxifen-resistant breast cancer and promotes cell proliferation and invasion in a cell line-specific manner, supporting its role as a key factor and potential therapeutic target. This evidence concerns the gene IGF2 and breast carcinoma.